Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report sent to investors on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on TENX. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Tenax Therapeutics Stock Performance

Shares of TENX opened at $5.46 on Monday. Tenax Therapeutics has a 52 week low of $2.77 and a 52 week high of $7.89. The stock has a market capitalization of $21.68 million, a price-to-earnings ratio of -1.03 and a beta of 1.88. The stock has a fifty day moving average of $6.32 and a 200-day moving average of $5.63.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.34. As a group, equities analysts forecast that Tenax Therapeutics will post -0.88 EPS for the current year.

Institutional Trading of Tenax Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics in the 4th quarter valued at $84,000. Millennium Management LLC bought a new stake in Tenax Therapeutics during the fourth quarter valued at $166,000. Janus Henderson Group PLC bought a new stake in Tenax Therapeutics during the fourth quarter valued at $1,026,000. Finally, Geode Capital Management LLC grew its holdings in Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after acquiring an additional 5,964 shares during the period. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.